AIM: £4.50 (-0.09) | Nasdaq: $29.01 (-0.22)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Career
Career Opportunities
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Career
Career Opportunities
Terms of Reference & Policies
Chi-Med
Shareholder Information
| Terms of Reference & Policies
Audit Committee - Terms of Reference
Nomination Committee - Terms of Reference
Remuneration Committee - Terms of Reference
Technical Committee - Terms of Reference
Board Diversity Policy
Code of Ethics
Code of Ethics – Business Partners
Tax Strategy
Complaints Procedures
Information Security Policy
Confidential & Price-Sensitive Insider Information and Securities Dealing Policies
Statement of Compliance with the UK Corporate Governance Code